Timing matters in diagnosis of cancer with immune-mediated inflammatory disease

IF 32.7 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2025-07-24 DOI:10.1038/s41584-025-01288-9

Dongxue Wang, Jianguang Ji

引用次数: 0

Abstract

Immune-mediated inflammatory diseases (IMIDs) are associated with cancer risk through mechanisms involving disrupted immune tolerance and dysregulated immune responses. Deng et al. investigated how the timing of IMID diagnosis relative to cancer diagnosis affects patient survival outcomes.

查看原文本刊更多论文

癌症伴免疫介导炎性疾病诊断的时机问题

免疫介导的炎症性疾病（IMIDs）通过涉及免疫耐受中断和免疫反应失调的机制与癌症风险相关。Deng等人研究了相对于癌症诊断的IMID诊断时间如何影响患者的生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.